Active Ingredient(s): Guselkumab
FDA Approved: * July 13, 2017
Pharm Company: * JANSSEN BIOTECH
Category: Immunosuppressive

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tremfya Overview

Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis.[5][6] Contents 1 Medical uses 2 Adverse effects 3 Pharmacology 3.1 Mechanism of action 3.2 Pharmacokinetics 4 Commercialization 4.1 Cost 4.2 Research and development 5 References 6 External links Medical uses Guselkumab is indicated to treat moderate to severe plaque psoriasis, and psoriatic arthritis in adults....

Read more Tremfya Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Tremfya Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 100mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tremfya: (1 result)

Sorted by National Drug Code
  • 57894-640 Tremfya 100 mg/ml Subcutaneous Injection by Janssen Biotech, Inc.

Other drugs which contain Guselkumab or a similar ingredient: (1 result)